肝移植作为一种有效的治疗手段广泛地应用于儿童终末期肝病的治疗。为了预防可能发生的排斥反应，患儿需要长期服用免疫抑制剂。他克莫司是一种具有强效免疫抑制特性的大环内酯类药物，以他克莫司为主的免疫抑制方案可以减少排斥反应和激素抵抗型排斥反应的发生率。探讨了基因多态性、减少剂量或撤药、不同剂型之间转换以及免疫抑制剂短期、长期生存结果对儿童肝移植术后的影响，以期优化他克莫司的给药方案，为器官移植患儿的他克莫司药物监测和剂量调整提供参考。

As an effective treatment,liver transplantation is widely used in the treatment of end-stage liver disease in children.In order to prevent possible rejection,children need to take long-term immunosuppressants.Tacrolimus is a macrolide drug with strong immunosuppressive properties,and the tacrolimus-based immunosuppressant regimen can reduce the incidence of rejection and hormone resistant rejection.This article discusses the effects of gene polymorphism,dose reduction or withdrawal,conversion between different dosage forms,and short-term and long-term survival results of immunosuppressants on children after liver transplantation,hoping to optimize the drug delivery scheme of tacrolimus,and provide reference for drug monitoring and dose adjustment of tacrolimus in children undergoing organ transplantation.